June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Clinical Outcomes in Patients with Necrotizing Scleritis at a Tertiary Academic Center
Author Affiliations & Notes
  • Joolie Nguyen
    Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
  • Krishna Mallem
    Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
    Division of Ocular Immunology, Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Benjamin Chaon
    Division of Ocular Immunology, Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Bryn Burkholder
    Division of Ocular Immunology, Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Jennifer Thorne
    Division of Ocular Immunology, Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
    Division of Clinical Trials, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States
  • Meghan Berkenstock
    Division of Ocular Immunology, Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Joolie Nguyen None; Krishna Mallem None; Benjamin Chaon None; Bryn Burkholder None; Jennifer Thorne None; Meghan Berkenstock None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4851. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joolie Nguyen, Krishna Mallem, Benjamin Chaon, Bryn Burkholder, Jennifer Thorne, Meghan Berkenstock; Clinical Outcomes in Patients with Necrotizing Scleritis at a Tertiary Academic Center. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4851.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Necrotizing scleritis represents the most severe form of anterior scleritis and can result in scleral perforation, requiring surgical management. We evaluated the clinical course of patients with necrotizing scleritis to determine risk factors for perforation.

Methods : Retrospective study of 35 patients (70 eyes) seen by the physicians of the Department of Ocular Immunology and Uveitis at the Wilmer Eye Institute from January 2006 to September 2022. Data collected demographic information, immunosuppressive medications and doses, whether perforation occurred, and surgical management.

Results : Median age at presentation was 69 years; 57% of patients were male. Caucasians comprised 63% of patients and the median duration of ocular symptoms prior to presentation was 4 months. Infectious scleritis was diagnosed in 6 patients (17%). A systemic illness was present in 18 patients (51%), with the most prevalent being an ANCA associated vasculitis followed by rheumatoid arthritis. Of the 70 eyes examined at baseline, 39 (57%) had scleral thinning at presentation, and 4 eyes (6%) had perforated prior to perforation. During follow-up 2 eyes perforated in a median time of 10 days from presentation. Surgical management consisted of three repeated patch grafts in one eye and no surgery performed in the other eye. At the time of perforation both patients were on oral prednisone at a median dose of 47.5 mg. Only one of the patients was on systemic immunosuppressant medication (100 mg/daily oral Cytoxan). In patients who experienced perforation in at least one eye prior to presentation or during follow-up, 33% (N=2) had an underlying systemic illness.

Conclusions : The percent of patients with necrotizing scleritis requiring surgical management decreases with aggressive initiation of prednisone with combination immunosuppressive therapy. Infectious scleritis is common and must be appropriately ruled out and treated prior to beginning immunosuppressive therapy. Long term immunosuppressive therapy is especially useful to reduce the risk for perforation, especially in those with an underlying autoimmune disorder.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×